<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="description" content="Scientific analysis of whether RhoGAM (Rh immune globulin) should be housed in the hospital blood bank or pharmacy. Evidence-based recommendations based on FDA regulations, AABB standards, and patient safety data.">
  <meta name="author" content="AI-Assisted Research">
  <meta property="og:title" content="RhoGAM: Blood Bank or Pharmacy? A Scientific Analysis">
  <meta property="og:description" content="Evidence-based analysis of RhoGAM storage and management in hospitals">
  <meta property="og:type" content="article">
  <title>RhoGAM: Should It Be Housed in the Blood Bank or Pharmacy?</title>
  <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
  <style>
    :root {
      --color-primary: #1e3a5f;
      --color-primary-light: #3b82f6;
      --color-bloodbank: #dc2626;
      --color-pharmacy: #3b82f6;
      --color-success: #059669;
      --color-warning: #f59e0b;
      --color-text: #1F2937;
      --color-text-light: #64748b;
      --color-bg: #FFFFFF;
      --color-bg-alt: #f8fafc;
      --color-bg-section: #f1f5f9;
      --color-border: #E5E7EB;
      --font-sans: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
      --max-width: 900px;
      --nav-width: 280px;
    }

    [data-theme="dark"] {
      --color-text: #F9FAFB;
      --color-text-light: #9CA3AF;
      --color-bg: #0f172a;
      --color-bg-alt: #1e293b;
      --color-bg-section: #1e293b;
      --color-border: #374151;
    }

    *, *::before, *::after { box-sizing: border-box; }

    html { scroll-behavior: smooth; }

    body {
      font-family: var(--font-sans);
      color: var(--color-text);
      background: var(--color-bg);
      line-height: 1.7;
      margin: 0;
      padding: 0;
    }

    .reading-progress {
      position: fixed;
      top: 0;
      left: 0;
      width: 0%;
      height: 4px;
      background: linear-gradient(90deg, var(--color-bloodbank), var(--color-pharmacy));
      z-index: 1000;
      transition: width 0.1s;
    }

    .page-wrapper {
      display: flex;
      max-width: 1400px;
      margin: 0 auto;
    }

    .sidebar {
      width: var(--nav-width);
      position: fixed;
      top: 0;
      left: 0;
      height: 100vh;
      padding: 2rem 1.5rem;
      background: var(--color-bg-alt);
      border-right: 1px solid var(--color-border);
      overflow-y: auto;
      display: none;
      z-index: 100;
    }

    @media (min-width: 1200px) {
      .sidebar { display: block; }
      .main-content { margin-left: var(--nav-width); }
    }

    .sidebar-header {
      margin-bottom: 1.5rem;
      padding-bottom: 1rem;
      border-bottom: 1px solid var(--color-border);
    }

    .sidebar-header h2 {
      font-size: 1rem;
      color: var(--color-primary);
      margin: 0;
    }

    .toc-list {
      list-style: none;
      padding: 0;
      margin: 0;
    }

    .toc-item { margin: 0.25rem 0; }

    .toc-link {
      display: block;
      color: var(--color-text-light);
      text-decoration: none;
      font-size: 0.85rem;
      padding: 0.5rem 0.75rem;
      border-radius: 6px;
      transition: all 0.2s;
    }

    .toc-link:hover {
      background: var(--color-bg-section);
      color: var(--color-primary-light);
    }

    .toc-link.active {
      background: var(--color-primary-light);
      color: white;
    }

    .toc-link.h3 { padding-left: 1.5rem; font-size: 0.8rem; }

    .main-content {
      flex: 1;
      max-width: var(--max-width);
      padding: 2rem;
      margin: 0 auto;
    }

    .article-header {
      text-align: center;
      margin-bottom: 3rem;
      padding-bottom: 2rem;
      border-bottom: 1px solid var(--color-border);
    }

    .article-header h1 {
      font-size: 2.5rem;
      color: var(--color-primary);
      margin-bottom: 1rem;
      line-height: 1.2;
    }

    .article-meta {
      display: flex;
      justify-content: center;
      gap: 2rem;
      color: var(--color-text-light);
      font-size: 0.9rem;
    }

    .meta-item {
      display: flex;
      align-items: center;
      gap: 0.5rem;
    }

    .lead-text {
      font-size: 1.2rem;
      color: var(--color-text-light);
      line-height: 1.8;
      margin-bottom: 2rem;
    }

    h2 {
      font-size: 1.75rem;
      color: var(--color-primary);
      margin-top: 3rem;
      margin-bottom: 1rem;
      padding-bottom: 0.5rem;
      border-bottom: 2px solid var(--color-border);
    }

    h3 {
      font-size: 1.25rem;
      color: var(--color-primary);
      margin-top: 2rem;
      margin-bottom: 0.75rem;
    }

    p { margin: 1.25rem 0; }

    strong { color: var(--color-primary); }

    blockquote {
      border-left: 4px solid var(--color-primary-light);
      margin: 2rem 0;
      padding: 1rem 1.5rem;
      background: var(--color-bg-alt);
      border-radius: 0 8px 8px 0;
      font-style: italic;
    }

    blockquote p { margin: 0; }

    blockquote cite {
      display: block;
      margin-top: 0.75rem;
      font-size: 0.85rem;
      color: var(--color-text-light);
      font-style: normal;
    }

    ul, ol {
      margin: 1rem 0;
      padding-left: 1.5rem;
    }

    li { margin: 0.5rem 0; }

    .key-point {
      background: linear-gradient(135deg, #ecfdf5 0%, #d1fae5 100%);
      border-left: 4px solid var(--color-success);
      padding: 1rem 1.5rem;
      border-radius: 0 8px 8px 0;
      margin: 1.5rem 0;
    }

    [data-theme="dark"] .key-point {
      background: linear-gradient(135deg, #064e3b 0%, #065f46 100%);
    }

    .key-point h4 {
      color: var(--color-success);
      margin: 0 0 0.5rem 0;
      font-size: 1rem;
    }

    .key-point p { margin: 0; }

    .warning-box {
      background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
      border-left: 4px solid var(--color-warning);
      padding: 1rem 1.5rem;
      border-radius: 0 8px 8px 0;
      margin: 1.5rem 0;
    }

    [data-theme="dark"] .warning-box {
      background: linear-gradient(135deg, #78350f 0%, #92400e 100%);
    }

    .viz-section {
      margin: 2.5rem 0;
      background: var(--color-bg-alt);
      border-radius: 16px;
      overflow: hidden;
      box-shadow: 0 4px 24px rgba(0,0,0,0.08);
    }

    .viz-embed {
      padding: 0;
    }

    .viz-embed figure {
      margin: 0;
      padding: 32px;
    }

    .takeaways {
      background: linear-gradient(135deg, var(--color-bg-alt) 0%, var(--color-bg-section) 100%);
      border-radius: 16px;
      padding: 2rem;
      margin: 2rem 0;
    }

    .takeaways h2 {
      border: none;
      margin-top: 0;
      text-align: center;
    }

    .takeaways ul {
      list-style: none;
      padding: 0;
    }

    .takeaways li {
      display: flex;
      align-items: flex-start;
      gap: 1rem;
      padding: 1rem;
      background: var(--color-bg);
      border-radius: 8px;
      margin: 0.75rem 0;
      box-shadow: 0 2px 8px rgba(0,0,0,0.04);
    }

    .takeaways li::before {
      content: '‚úì';
      display: flex;
      align-items: center;
      justify-content: center;
      min-width: 28px;
      height: 28px;
      background: var(--color-success);
      color: white;
      border-radius: 50%;
      font-weight: bold;
      font-size: 0.85rem;
    }

    .sources-section {
      margin-top: 3rem;
      padding-top: 2rem;
      border-top: 2px solid var(--color-border);
    }

    .sources-grid {
      display: grid;
      gap: 0.5rem;
    }

    .source-item {
      display: flex;
      gap: 0.75rem;
      padding: 0.75rem;
      background: var(--color-bg-alt);
      border-radius: 8px;
      font-size: 0.85rem;
    }

    .source-num {
      min-width: 28px;
      height: 28px;
      display: flex;
      align-items: center;
      justify-content: center;
      background: var(--color-primary-light);
      color: white;
      border-radius: 4px;
      font-size: 0.75rem;
      font-weight: 600;
    }

    .source-item a {
      color: var(--color-primary-light);
      text-decoration: none;
    }

    .source-item a:hover { text-decoration: underline; }

    .back-to-top {
      position: fixed;
      bottom: 2rem;
      right: 2rem;
      background: var(--color-primary);
      color: white;
      border: none;
      border-radius: 50%;
      width: 48px;
      height: 48px;
      cursor: pointer;
      opacity: 0;
      transition: opacity 0.3s, transform 0.3s;
      font-size: 1.25rem;
      box-shadow: 0 4px 12px rgba(0,0,0,0.2);
      z-index: 100;
    }

    .back-to-top:hover { transform: scale(1.1); }
    .back-to-top.visible { opacity: 1; }

    .theme-toggle {
      position: fixed;
      top: 1rem;
      right: 1rem;
      background: var(--color-bg-alt);
      border: 1px solid var(--color-border);
      border-radius: 8px;
      padding: 0.5rem 1rem;
      cursor: pointer;
      font-size: 1.25rem;
      z-index: 100;
    }

    .mobile-nav-toggle {
      display: none;
      position: fixed;
      top: 1rem;
      left: 1rem;
      background: var(--color-bg-alt);
      border: 1px solid var(--color-border);
      border-radius: 8px;
      padding: 0.5rem 1rem;
      cursor: pointer;
      z-index: 101;
    }

    @media (max-width: 1199px) {
      .mobile-nav-toggle { display: block; }
      .sidebar.open { display: block; }
    }

    @media (max-width: 768px) {
      .article-header h1 { font-size: 1.75rem; }
      .lead-text { font-size: 1rem; }
      h2 { font-size: 1.5rem; }
      .main-content { padding: 1rem; }
      .article-meta { flex-direction: column; gap: 0.5rem; }
    }

    @media print {
      .sidebar, .back-to-top, .theme-toggle, .reading-progress, .mobile-nav-toggle { display: none !important; }
      .main-content { margin-left: 0; max-width: 100%; }
      .viz-section { break-inside: avoid; }
    }

    /* Viz container resets for embedding */
    .viz-embed .viz-container {
      max-width: 100%;
      box-shadow: none;
      border-radius: 0;
    }

    .viz-embed body {
      background: transparent;
      min-height: auto;
      padding: 0;
    }

    /* Timeline styles */
    .timeline { position: relative; padding: 20px 0; }
    .timeline::before {
      content: '';
      position: absolute;
      left: 50%;
      transform: translateX(-50%);
      width: 4px;
      height: 100%;
      background: linear-gradient(to bottom, #dc2626, #f97316, #eab308, #22c55e);
      border-radius: 2px;
    }
    .timeline-item {
      position: relative;
      margin-bottom: 40px;
      width: 45%;
      padding: 20px;
      background: #f8fafc;
      border-radius: 12px;
      border-left: 4px solid;
      transition: all 0.3s ease;
      cursor: pointer;
    }
    .timeline-item:hover {
      transform: translateY(-4px);
      box-shadow: 0 8px 24px rgba(0,0,0,0.12);
    }
    .timeline-item:nth-child(odd) { margin-left: 5%; }
    .timeline-item:nth-child(even) { margin-left: 50%; }
    .timeline-item.era-pre { border-color: #dc2626; background: linear-gradient(135deg, #fef2f2 0%, #fee2e2 100%); }
    .timeline-item.era-discovery { border-color: #f97316; background: linear-gradient(135deg, #fff7ed 0%, #ffedd5 100%); }
    .timeline-item.era-approval { border-color: #eab308; background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%); }
    .timeline-item.era-modern { border-color: #22c55e; background: linear-gradient(135deg, #f0fdf4 0%, #dcfce7 100%); }
    .timeline-dot {
      position: absolute;
      width: 20px;
      height: 20px;
      border-radius: 50%;
      background: white;
      border: 4px solid;
      top: 24px;
    }
    .timeline-item:nth-child(odd) .timeline-dot { right: -32px; }
    .timeline-item:nth-child(even) .timeline-dot { left: -32px; }
    .timeline-item.era-pre .timeline-dot { border-color: #dc2626; }
    .timeline-item.era-discovery .timeline-dot { border-color: #f97316; }
    .timeline-item.era-approval .timeline-dot { border-color: #eab308; }
    .timeline-item.era-modern .timeline-dot { border-color: #22c55e; }
    .timeline-year { font-size: 1.5rem; font-weight: 700; margin-bottom: 8px; }
    .timeline-item.era-pre .timeline-year { color: #dc2626; }
    .timeline-item.era-discovery .timeline-year { color: #f97316; }
    .timeline-item.era-approval .timeline-year { color: #eab308; }
    .timeline-item.era-modern .timeline-year { color: #22c55e; }
    .timeline-title { font-size: 1.1rem; font-weight: 600; color: #1e293b; margin-bottom: 8px; }
    .timeline-desc { font-size: 0.9rem; color: #64748b; line-height: 1.5; }
    .timeline-stat {
      display: inline-block;
      margin-top: 12px;
      padding: 6px 12px;
      background: rgba(0,0,0,0.05);
      border-radius: 20px;
      font-size: 0.85rem;
      font-weight: 600;
    }
    .legend {
      display: flex;
      justify-content: center;
      gap: 24px;
      margin-top: 32px;
      flex-wrap: wrap;
    }
    .legend-item { display: flex; align-items: center; gap: 8px; font-size: 0.85rem; color: #64748b; }
    .legend-dot { width: 12px; height: 12px; border-radius: 50%; }
    .legend-dot.pre { background: #dc2626; }
    .legend-dot.discovery { background: #f97316; }
    .legend-dot.approval { background: #eab308; }
    .legend-dot.modern { background: #22c55e; }

    @media (max-width: 768px) {
      .timeline::before { left: 20px; }
      .timeline-item { width: calc(100% - 50px); margin-left: 50px !important; }
      .timeline-item .timeline-dot { left: -42px !important; right: auto !important; }
    }

    /* Hierarchy styles */
    .hierarchy { display: flex; flex-direction: column; align-items: center; gap: 24px; }
    .level { display: flex; justify-content: center; gap: 20px; flex-wrap: wrap; width: 100%; }
    .connector { width: 2px; height: 24px; background: linear-gradient(to bottom, #3b82f6, #64748b); }
    .node {
      padding: 16px 24px;
      border-radius: 12px;
      text-align: center;
      cursor: pointer;
      transition: all 0.3s ease;
      position: relative;
      min-width: 200px;
    }
    .node:hover { transform: translateY(-4px); box-shadow: 0 8px 24px rgba(0,0,0,0.15); }
    .node.federal { background: linear-gradient(135deg, #1e40af 0%, #3b82f6 100%); color: white; }
    .node.professional { background: linear-gradient(135deg, #0f766e 0%, #14b8a6 100%); color: white; }
    .node.accreditation { background: linear-gradient(135deg, #7c3aed 0%, #a78bfa 100%); color: white; }
    .node.state { background: linear-gradient(135deg, #c2410c 0%, #f97316 100%); color: white; }
    .node.institutional { background: linear-gradient(135deg, #4b5563 0%, #9ca3af 100%); color: white; }
    .node-title { font-size: 1rem; font-weight: 700; margin-bottom: 4px; }
    .node-subtitle { font-size: 0.75rem; opacity: 0.9; }
    .node-badge {
      position: absolute;
      top: -8px;
      right: -8px;
      background: #fbbf24;
      color: #1e293b;
      font-size: 0.65rem;
      font-weight: 700;
      padding: 4px 8px;
      border-radius: 12px;
      text-transform: uppercase;
    }
    .level-label { font-size: 0.75rem; color: #94a3b8; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 8px; text-align: center; }

    /* Flowchart styles */
    .flowchart { display: flex; flex-direction: column; align-items: center; gap: 8px; }
    .flow-step { display: flex; align-items: center; gap: 16px; width: 100%; max-width: 700px; }
    .step-number {
      width: 40px;
      height: 40px;
      min-width: 40px;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 1rem;
      color: white;
    }
    .step-box {
      flex: 1;
      padding: 16px 20px;
      border-radius: 12px;
      cursor: pointer;
      transition: all 0.3s ease;
      position: relative;
    }
    .step-box:hover { transform: translateX(8px); box-shadow: 0 4px 16px rgba(0,0,0,0.12); }
    .step-box h3 { font-size: 1rem; margin-bottom: 4px; margin-top: 0; border: none; padding: 0; }
    .step-box p { font-size: 0.85rem; opacity: 0.9; margin: 0; }
    .step-box .dept-badge {
      position: absolute;
      top: -8px;
      right: 16px;
      padding: 4px 10px;
      border-radius: 12px;
      font-size: 0.7rem;
      font-weight: 600;
      text-transform: uppercase;
    }
    .clinical .step-number { background: #6366f1; }
    .clinical .step-box { background: linear-gradient(135deg, #eef2ff 0%, #e0e7ff 100%); }
    .clinical .step-box h3 { color: #4338ca; }
    .clinical .dept-badge { background: #6366f1; color: white; }
    .bloodbank .step-number { background: #dc2626; }
    .bloodbank .step-box { background: linear-gradient(135deg, #fef2f2 0%, #fee2e2 100%); }
    .bloodbank .step-box h3 { color: #b91c1c; }
    .bloodbank .dept-badge { background: #dc2626; color: white; }
    .nursing .step-number { background: #059669; }
    .nursing .step-box { background: linear-gradient(135deg, #ecfdf5 0%, #d1fae5 100%); }
    .nursing .step-box h3 { color: #047857; }
    .nursing .dept-badge { background: #059669; color: white; }
    .arrow { width: 2px; height: 20px; background: #cbd5e1; margin-left: 19px; position: relative; }
    .arrow::after {
      content: '';
      position: absolute;
      bottom: 0;
      left: -4px;
      width: 0;
      height: 0;
      border-left: 5px solid transparent;
      border-right: 5px solid transparent;
      border-top: 8px solid #cbd5e1;
    }
    .decision-box { width: 100%; max-width: 700px; display: flex; flex-direction: column; align-items: center; }
    .decision {
      background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
      padding: 16px 24px;
      border-radius: 12px;
      text-align: center;
      border: 2px solid #f59e0b;
    }
    .decision h3 { color: #b45309; font-size: 0.95rem; margin: 0; border: none; padding: 0; }
    .decision-branches { display: flex; justify-content: center; gap: 80px; margin-top: 16px; }
    .branch { display: flex; flex-direction: column; align-items: center; }
    .branch-label { font-size: 0.8rem; font-weight: 600; padding: 4px 12px; border-radius: 8px; margin-bottom: 8px; }
    .branch-yes .branch-label { background: #dcfce7; color: #166534; }
    .branch-no .branch-label { background: #fee2e2; color: #991b1b; }
    .branch-arrow { width: 2px; height: 30px; background: #cbd5e1; }
    .critical-note {
      background: #fef2f2;
      border: 1px solid #fecaca;
      border-radius: 8px;
      padding: 12px 16px;
      margin-top: 24px;
      display: flex;
      align-items: center;
      gap: 12px;
    }
    .critical-note svg { width: 24px; height: 24px; fill: #dc2626; flex-shrink: 0; }
    .critical-note p { font-size: 0.85rem; color: #7f1d1d; margin: 0; }

    /* Stats styles */
    .stats-row { display: grid; grid-template-columns: repeat(3, 1fr); gap: 16px; margin-bottom: 32px; }
    .stat-card {
      background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
      padding: 20px;
      border-radius: 12px;
      text-align: center;
      border: 1px solid #e2e8f0;
    }
    .stat-value { font-size: 2rem; font-weight: 700; color: #1e3a5f; }
    .stat-value.highlight { color: #dc2626; }
    .stat-value.success { color: #059669; }
    .stat-label { font-size: 0.85rem; color: #64748b; margin-top: 4px; }
    .chart-wrapper { position: relative; width: 100%; max-width: 700px; margin: 0 auto; }
    .insights {
      margin-top: 32px;
      padding: 20px;
      background: linear-gradient(135deg, #eff6ff 0%, #dbeafe 100%);
      border-radius: 12px;
      border-left: 4px solid #3b82f6;
    }
    .insights h3 { color: #1e40af; font-size: 1rem; margin-bottom: 12px; margin-top: 0; border: none; padding: 0; }
    .insights ul { list-style: none; padding: 0; margin: 0; }
    .insights li { padding: 8px 0; color: #1e40af; font-size: 0.9rem; display: flex; align-items: flex-start; gap: 8px; margin: 0; }
    .insights li::before { content: '‚Üí'; color: #3b82f6; font-weight: bold; }
    .success-note {
      margin-top: 20px;
      padding: 16px;
      background: linear-gradient(135deg, #ecfdf5 0%, #d1fae5 100%);
      border-radius: 12px;
      border-left: 4px solid #059669;
      display: flex;
      align-items: center;
      gap: 12px;
    }
    .success-note svg { width: 32px; height: 32px; fill: #059669; flex-shrink: 0; }
    .success-note p { color: #047857; font-size: 0.9rem; margin: 0; }

    @media (max-width: 600px) {
      .stats-row { grid-template-columns: 1fr; }
      .stat-value { font-size: 1.5rem; }
      .decision-branches { gap: 40px; }
    }

    /* Comparison table styles */
    .comparison-table { width: 100%; border-collapse: collapse; margin-bottom: 24px; }
    .comparison-table th { padding: 16px; text-align: left; font-weight: 600; font-size: 0.95rem; }
    .comparison-table th:first-child { background: #f8fafc; color: #64748b; border-radius: 8px 0 0 0; width: 25%; }
    .comparison-table th.bloodbank { background: linear-gradient(135deg, #dc2626 0%, #ef4444 100%); color: white; text-align: center; width: 37.5%; }
    .comparison-table th.pharmacy { background: linear-gradient(135deg, #3b82f6 0%, #60a5fa 100%); color: white; text-align: center; border-radius: 0 8px 0 0; width: 37.5%; }
    .comparison-table td { padding: 14px 16px; border-bottom: 1px solid #f1f5f9; font-size: 0.9rem; vertical-align: top; }
    .comparison-table tr:last-child td { border-bottom: none; }
    .comparison-table td:first-child { font-weight: 600; color: #1e3a5f; background: #f8fafc; }
    .comparison-table td:nth-child(2) { background: #fef2f2; }
    .comparison-table td:nth-child(3) { background: #eff6ff; }
    .rating { display: flex; align-items: center; gap: 8px; }
    .rating-icon { width: 24px; height: 24px; border-radius: 50%; display: flex; align-items: center; justify-content: center; font-size: 14px; flex-shrink: 0; }
    .rating-icon.excellent { background: #dcfce7; color: #166534; }
    .rating-icon.good { background: #fef9c3; color: #854d0e; }
    .rating-icon.limited { background: #fee2e2; color: #991b1b; }
    .verdict { margin-top: 32px; display: grid; grid-template-columns: 1fr 1fr; gap: 24px; }
    .verdict-card { padding: 24px; border-radius: 12px; text-align: center; }
    .verdict-card.bloodbank { background: linear-gradient(135deg, #fef2f2 0%, #fee2e2 100%); border: 2px solid #fecaca; }
    .verdict-card.pharmacy { background: linear-gradient(135deg, #eff6ff 0%, #dbeafe 100%); border: 2px solid #bfdbfe; }
    .verdict-card h3 { font-size: 1.1rem; margin-bottom: 12px; margin-top: 0; border: none; padding: 0; }
    .verdict-card.bloodbank h3 { color: #991b1b; }
    .verdict-card.pharmacy h3 { color: #1e40af; }
    .verdict-card .score { font-size: 3rem; font-weight: 700; margin-bottom: 8px; }
    .verdict-card.bloodbank .score { color: #dc2626; }
    .verdict-card.pharmacy .score { color: #3b82f6; }
    .verdict-card p { font-size: 0.85rem; color: #64748b; margin: 0; }
    .recommendation {
      margin-top: 24px;
      padding: 20px;
      background: linear-gradient(135deg, #ecfdf5 0%, #d1fae5 100%);
      border-radius: 12px;
      border-left: 4px solid #059669;
      display: flex;
      align-items: flex-start;
      gap: 16px;
    }
    .recommendation svg { width: 32px; height: 32px; fill: #059669; flex-shrink: 0; }
    .recommendation-text h4 { color: #047857; margin-bottom: 8px; margin-top: 0; }
    .recommendation-text p { color: #065f46; font-size: 0.9rem; line-height: 1.5; margin: 0; }

    @media (max-width: 768px) {
      .comparison-table { display: block; overflow-x: auto; }
      .verdict { grid-template-columns: 1fr; }
    }

    /* Decision tree styles */
    .decision-tree { display: flex; flex-direction: column; align-items: center; gap: 0; }
    .decision-tree .node { position: relative; text-align: center; margin: 8px 0; }
    .question-node {
      background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
      border: 2px solid #f59e0b;
      padding: 16px 24px;
      border-radius: 12px;
      max-width: 400px;
      cursor: pointer;
      transition: all 0.3s ease;
    }
    .question-node:hover { transform: scale(1.02); box-shadow: 0 4px 16px rgba(245, 158, 11, 0.3); }
    .question-node h3 { color: #92400e; font-size: 1rem; margin-bottom: 4px; margin-top: 0; border: none; padding: 0; }
    .question-node p { color: #a16207; font-size: 0.8rem; margin: 0; }
    .decision-tree .branches { display: flex; justify-content: center; gap: 100px; position: relative; }
    .decision-tree .connector { width: 2px; height: 24px; background: #cbd5e1; }
    .outcome-node { padding: 12px 20px; border-radius: 8px; font-size: 0.85rem; font-weight: 600; max-width: 180px; }
    .outcome-node.stop { background: linear-gradient(135deg, #fee2e2 0%, #fecaca 100%); color: #991b1b; border: 2px solid #fca5a5; }
    .outcome-node.action { background: linear-gradient(135deg, #dbeafe 0%, #bfdbfe 100%); color: #1e40af; border: 2px solid #93c5fd; }
    .legend-box { width: 24px; height: 24px; border-radius: 6px; }
    .legend-box.question { background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%); border: 2px solid #f59e0b; }
    .legend-box.stop { background: linear-gradient(135deg, #fee2e2 0%, #fecaca 100%); border: 2px solid #fca5a5; }
    .legend-box.action { background: linear-gradient(135deg, #dbeafe 0%, #bfdbfe 100%); border: 2px solid #93c5fd; }

    @media (max-width: 768px) {
      .decision-tree .branches { gap: 40px; }
      .question-node { padding: 12px 16px; max-width: 300px; }
      .outcome-node { max-width: 140px; font-size: 0.75rem; padding: 8px 12px; }
    }

    /* Products grid styles */
    .products-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(280px, 1fr)); gap: 20px; margin-bottom: 24px; }
    .product-card {
      background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
      border-radius: 12px;
      padding: 24px;
      border: 1px solid #e2e8f0;
      transition: all 0.3s ease;
      cursor: pointer;
    }
    .product-card:hover { transform: translateY(-4px); box-shadow: 0 8px 24px rgba(0,0,0,0.1); border-color: #3b82f6; }
    .product-card.standard-dose { border-left: 4px solid #3b82f6; }
    .product-card.mini-dose { border-left: 4px solid #8b5cf6; }
    .product-header { display: flex; justify-content: space-between; align-items: flex-start; margin-bottom: 16px; }
    .product-name { font-size: 1.15rem; font-weight: 700; color: #1e3a5f; }
    .product-badge { padding: 4px 10px; border-radius: 12px; font-size: 0.7rem; font-weight: 600; text-transform: uppercase; }
    .product-badge.standard { background: #dbeafe; color: #1e40af; }
    .product-badge.mini { background: #ede9fe; color: #5b21b6; }
    .product-badge.iv-capable { background: #dcfce7; color: #166534; }
    .product-manufacturer { font-size: 0.85rem; color: #64748b; margin-bottom: 16px; }
    .product-details { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .detail-item { background: white; padding: 10px 12px; border-radius: 8px; }
    .detail-label { font-size: 0.7rem; color: #94a3b8; text-transform: uppercase; letter-spacing: 0.5px; margin-bottom: 4px; }
    .detail-value { font-size: 0.95rem; font-weight: 600; color: #1e3a5f; }
    .product-notes { margin-top: 16px; padding-top: 16px; border-top: 1px solid #e2e8f0; font-size: 0.85rem; color: #64748b; }
    .info-box {
      margin-top: 24px;
      padding: 20px;
      background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
      border-radius: 12px;
      border-left: 4px solid #f59e0b;
    }
    .info-box h3 { color: #92400e; font-size: 1rem; margin-bottom: 8px; margin-top: 0; border: none; padding: 0; }
    .info-box p { color: #a16207; font-size: 0.9rem; line-height: 1.5; margin: 0; }
    .dosing-note {
      margin-top: 24px;
      padding: 20px;
      background: linear-gradient(135deg, #eff6ff 0%, #dbeafe 100%);
      border-radius: 12px;
      border-left: 4px solid #3b82f6;
    }
    .dosing-note h3 { color: #1e40af; font-size: 1rem; margin-bottom: 12px; margin-top: 0; border: none; padding: 0; }
    .dosing-table { width: 100%; font-size: 0.85rem; }
    .dosing-table th { text-align: left; color: #64748b; font-weight: 500; padding: 8px 0; border-bottom: 1px solid #bfdbfe; }
    .dosing-table td { padding: 8px 0; color: #1e40af; }

    .viz-source { text-align: center; margin-top: 24px; font-size: 0.8rem; color: #94a3b8; }

    /* Modal/overlay styles for interactive hierarchy */
    .overlay {
      display: none;
      position: fixed;
      top: 0;
      left: 0;
      right: 0;
      bottom: 0;
      background: rgba(0,0,0,0.5);
      z-index: 999;
    }
    .overlay.active { display: block; }
    .detail-panel {
      display: none;
      position: fixed;
      top: 50%;
      left: 50%;
      transform: translate(-50%, -50%);
      background: white;
      padding: 32px;
      border-radius: 16px;
      box-shadow: 0 24px 48px rgba(0,0,0,0.2);
      max-width: 500px;
      width: 90%;
      z-index: 1000;
    }
    .detail-panel.active { display: block; }
    .detail-panel h3 { color: #1e3a5f; margin-bottom: 16px; }
    .detail-panel p { color: #64748b; line-height: 1.6; margin-bottom: 12px; }
    .detail-panel .key-point {
      background: #f0f9ff;
      padding: 12px;
      border-radius: 8px;
      border-left: 4px solid #3b82f6;
      margin-top: 16px;
    }
    .close-btn {
      position: absolute;
      top: 16px;
      right: 16px;
      background: none;
      border: none;
      font-size: 1.5rem;
      cursor: pointer;
      color: #94a3b8;
    }
  </style>
</head>
<body>
  <div class="reading-progress" id="progress"></div>

  <button class="theme-toggle" onclick="toggleTheme()" aria-label="Toggle dark mode">üåì</button>
  <button class="mobile-nav-toggle" onclick="toggleSidebar()" aria-label="Toggle navigation">‚ò∞</button>

  <div class="overlay" id="overlay" onclick="closePanel()"></div>

  <div class="page-wrapper">
    <nav class="sidebar" id="sidebar" aria-label="Table of Contents">
      <div class="sidebar-header">
        <h2>Contents</h2>
      </div>
      <ul class="toc-list">
        <li class="toc-item"><a href="#understanding" class="toc-link">Understanding RhoGAM</a></li>
        <li class="toc-item"><a href="#what-is-rhig" class="toc-link h3">What Is Rh Immune Globulin?</a></li>
        <li class="toc-item"><a href="#historical-impact" class="toc-link h3">Historical Impact</a></li>
        <li class="toc-item"><a href="#regulatory" class="toc-link">Regulatory Landscape</a></li>
        <li class="toc-item"><a href="#fda" class="toc-link h3">FDA Classification</a></li>
        <li class="toc-item"><a href="#aabb" class="toc-link h3">AABB Standards</a></li>
        <li class="toc-item"><a href="#jc" class="toc-link h3">Joint Commission</a></li>
        <li class="toc-item"><a href="#blood-bank-case" class="toc-link">Case for Blood Bank</a></li>
        <li class="toc-item"><a href="#testing" class="toc-link h3">Testing Requirements</a></li>
        <li class="toc-item"><a href="#dosing" class="toc-link h3">Dosing Expertise</a></li>
        <li class="toc-item"><a href="#safety" class="toc-link h3">Patient Safety Data</a></li>
        <li class="toc-item"><a href="#pharmacy-case" class="toc-link">Case for Pharmacy</a></li>
        <li class="toc-item"><a href="#hybrid" class="toc-link">Hybrid Model</a></li>
        <li class="toc-item"><a href="#products" class="toc-link">Available Products</a></li>
        <li class="toc-item"><a href="#takeaways" class="toc-link">Key Takeaways</a></li>
        <li class="toc-item"><a href="#conclusion" class="toc-link">Conclusion</a></li>
        <li class="toc-item"><a href="#sources" class="toc-link">Sources</a></li>
      </ul>
    </nav>

    <main class="main-content">
      <article>
        <header class="article-header">
          <h1>RhoGAM: Should It Be Housed in the Blood Bank or Pharmacy?</h1>
          <div class="article-meta">
            <span class="meta-item">üìÖ January 2026</span>
            <span class="meta-item">‚è±Ô∏è 15 min read</span>
            <span class="meta-item">üìä 32 sources</span>
          </div>
        </header>

        <p class="lead-text">In 1968, a revolutionary medical breakthrough transformed obstetric care: the introduction of RhoGAM (Rh immune globulin) reduced the devastating impact of hemolytic disease of the fetus and newborn by over 80%. Today, this life-saving product prevents approximately 10,000 fetal deaths annually in the United States alone. Yet behind the scenes of every hospital, a seemingly mundane question creates significant operational and safety implications: <strong>Should RhoGAM be stored and dispensed by the blood bank or the pharmacy?</strong></p>

        <p>This question has sparked debate among hospital administrators, blood bank directors, pharmacy leaders, and accreditation surveyors. Some Joint Commission surveyors have told hospitals that RhoGAM "must" be under pharmacy control, while AABB standards explicitly require the transfusion service to maintain RhIG policies. The answer, as this evidence-based analysis reveals, is nuanced‚Äîbut the scientific data strongly supports blood bank management as the safer and more effective approach.</p>

        <h2 id="understanding">Understanding RhoGAM: More Than Just Another Medication</h2>

        <h3 id="what-is-rhig">What Is Rh Immune Globulin?</h3>

        <p>Rh immune globulin (RhIG), sold under brand names including RhoGAM, MICRhoGAM, Rhophylac, WinRho, and HyperRHO, is a plasma-derived biologic product containing concentrated anti-D antibodies. It is manufactured from human plasma collected from Rh-negative donors who have been immunized with Rh-positive red blood cells. This product prevents Rh-negative mothers from developing antibodies against the Rh-positive blood cells of their babies‚Äîa condition that, if left untreated, can cause severe anemia, brain damage, or death in subsequent pregnancies.</p>

        <p>The standard 300-microgram dose of RhIG can neutralize up to 15 mL of fetal red blood cells (equivalent to 30 mL of whole fetal blood), providing protection for approximately 21 days. Administration is typically recommended at 28 weeks of pregnancy and again within 72 hours of delivering an Rh-positive infant.</p>

        <h3 id="historical-impact">The Historical Impact of RhIG</h3>

        <!-- Timeline Visualization -->
        <div class="viz-section">
          <div class="viz-embed">
            <figure id="viz-1">
              <div class="viz-header" style="text-align: center; margin-bottom: 32px;">
                <h1 style="font-size: 1.75rem; color: #1e3a5f; margin-bottom: 8px;">The Journey to Preventing Hemolytic Disease</h1>
                <p style="color: #64748b; font-size: 0.95rem;">Historical Timeline of RhIG Development and HDFN Reduction</p>
              </div>

              <div class="timeline">
                <div class="timeline-item era-pre">
                  <div class="timeline-dot"></div>
                  <div class="timeline-year">1940</div>
                  <div class="timeline-title">Rh Blood Group System Discovered</div>
                  <div class="timeline-desc">Landsteiner and Wiener identify the Rh factor, laying the groundwork for understanding hemolytic disease.</div>
                </div>

                <div class="timeline-item era-pre">
                  <div class="timeline-dot"></div>
                  <div class="timeline-year">1945</div>
                  <div class="timeline-title">Peak Mortality Era</div>
                  <div class="timeline-desc">Approximately 50% of fetuses with hemolytic disease die from kernicterus or hydrops fetalis.</div>
                  <span class="timeline-stat">50% fetal mortality</span>
                </div>

                <div class="timeline-item era-discovery">
                  <div class="timeline-dot"></div>
                  <div class="timeline-year">1961</div>
                  <div class="timeline-title">Prevention Concept Proven</div>
                  <div class="timeline-desc">Stern and colleagues demonstrate that anti-D IgG can prevent Rh sensitization in mothers.</div>
                </div>

                <div class="timeline-item era-discovery">
                  <div class="timeline-dot"></div>
                  <div class="timeline-year">1964</div>
                  <div class="timeline-title">Clinical Trials Published</div>
                  <div class="timeline-desc">Freda, Gorman, and Pollack publish successful prevention studies using anti-Rh gamma-globulin.</div>
                </div>

                <div class="timeline-item era-approval">
                  <div class="timeline-dot"></div>
                  <div class="timeline-year">1968</div>
                  <div class="timeline-title">RhoGAM Approved by FDA</div>
                  <div class="timeline-desc">First RhoGAM administration on May 29, 1968. FDA grants regulatory approval, marking a new era in obstetric care.</div>
                  <span class="timeline-stat">FDA Approved</span>
                </div>

                <div class="timeline-item era-approval">
                  <div class="timeline-dot"></div>
                  <div class="timeline-year">1970s</div>
                  <div class="timeline-title">Antepartum Prophylaxis Added</div>
                  <div class="timeline-desc">Routine 28-week administration introduced, further reducing sensitization rates.</div>
                  <span class="timeline-stat">80-90% reduction in HDFN</span>
                </div>

                <div class="timeline-item era-modern">
                  <div class="timeline-dot"></div>
                  <div class="timeline-year">2020s</div>
                  <div class="timeline-title">Near-Complete Prevention</div>
                  <div class="timeline-desc">Combined antenatal and postpartum prophylaxis achieves approximately 99% effectiveness at preventing maternal sensitization.</div>
                  <span class="timeline-stat">0.1-0.2% alloimmunization rate</span>
                </div>
              </div>

              <div class="legend">
                <div class="legend-item"><div class="legend-dot pre"></div><span>Pre-Prevention Era</span></div>
                <div class="legend-item"><div class="legend-dot discovery"></div><span>Discovery Phase</span></div>
                <div class="legend-item"><div class="legend-dot approval"></div><span>Approval & Implementation</span></div>
                <div class="legend-item"><div class="legend-dot modern"></div><span>Modern Era</span></div>
              </div>

              <figcaption class="viz-source">
                <strong>Figure 1:</strong> Timeline of RhIG development showing dramatic reduction in HDFN mortality.<br>
                Sources: PMC, PLOS ONE, Springer, NCBI StatPearls
              </figcaption>
            </figure>
          </div>
        </div>

        <p>Before the introduction of RhIG, hemolytic disease of the fetus and newborn (HDFN) was a major cause of fetal and neonatal mortality. Prior to 1945, approximately 50% of all fetuses with hemolytic diseases died of kernicterus or hydrops fetalis. The global incidence of HDFN was estimated at around 1% of all pregnancies, with a mortality rate approaching 50%.</p>

        <p>The development of RhIG represents one of medicine's greatest preventive success stories. Since its introduction in 1968, combined antenatal and postpartum prophylaxis has achieved approximately <strong>99% effectiveness</strong> in preventing maternal sensitization. The incidence of Rh-hemolytic disease has declined by 80-90%, and mortality rates have dropped by two-thirds.</p>

        <blockquote>
          <p>"Given the serious nature of Rh-alloimmunization, researchers believe missed prophylaxis should be a 'never event.'"</p>
          <cite>‚Äî PMC Study on Missed Anti-D Administration</cite>
        </blockquote>

        <h2 id="regulatory">The Regulatory Landscape: Classification Confusion</h2>

        <h3 id="fda">FDA Classification</h3>

        <p>RhoGAM occupies a unique regulatory space. It is licensed under Biologics License Application (BLA) 103777 and regulated by the FDA's Center for Biologics Evaluation and Research (CBER). Critically, RhIG is regulated under <strong>21 CFR Part 640 Subpart J</strong> (Immune Globulin Human)‚Äînot under Part 606, which governs blood and blood components.</p>

        <p>This distinction matters because it classifies RhIG as a <strong>plasma derivative</strong> rather than a blood component. Plasma derivatives, like other immunoglobulin products (IVIG), albumin, and clotting factors, are manufactured through fractionation processes from large donor pools and undergo viral inactivation. In contrast, blood components (whole blood, red cells, platelets, plasma) are prepared from individual donations with minimal processing.</p>

        <!-- Regulatory Hierarchy Visualization -->
        <div class="viz-section">
          <div class="viz-embed">
            <figure id="viz-2">
              <div class="viz-header" style="text-align: center; margin-bottom: 32px;">
                <h1 style="font-size: 1.75rem; color: #1e3a5f; margin-bottom: 8px;">Regulatory Framework for RhIG Management</h1>
                <p style="color: #64748b; font-size: 0.95rem;">Click on any box to learn more about its requirements</p>
              </div>

              <div class="hierarchy">
                <div class="level-label">Federal Oversight</div>
                <div class="level">
                  <div class="node federal" onclick="showDetail('fda')">
                    <div class="node-title">FDA / CBER</div>
                    <div class="node-subtitle">21 CFR Part 640</div>
                  </div>
                </div>

                <div class="connector"></div>

                <div class="level-label">Professional Standards</div>
                <div class="level">
                  <div class="node professional" onclick="showDetail('aabb')">
                    <div class="node-badge">Key</div>
                    <div class="node-title">AABB Standards</div>
                    <div class="node-subtitle">Standard 5.30</div>
                  </div>
                </div>

                <div class="connector"></div>

                <div class="level-label">Accreditation</div>
                <div class="level">
                  <div class="node accreditation" onclick="showDetail('cap')">
                    <div class="node-title">CAP</div>
                    <div class="node-subtitle">TRM Checklist</div>
                  </div>
                  <div class="node accreditation" onclick="showDetail('jc')">
                    <div class="node-badge">Flexible</div>
                    <div class="node-title">Joint Commission</div>
                    <div class="node-subtitle">Either Standard OK</div>
                  </div>
                </div>

                <div class="connector"></div>

                <div class="level-label">State Level</div>
                <div class="level">
                  <div class="node state" onclick="showDetail('state')">
                    <div class="node-title">State Regulations</div>
                    <div class="node-subtitle">Variable by Jurisdiction</div>
                  </div>
                </div>

                <div class="connector"></div>

                <div class="level-label">Institutional</div>
                <div class="level">
                  <div class="node institutional" onclick="showDetail('hospital')">
                    <div class="node-title">Hospital Policies</div>
                    <div class="node-subtitle">Blood Bank or Pharmacy</div>
                  </div>
                </div>
              </div>

              <figcaption class="viz-source">
                <strong>Figure 2:</strong> Regulatory hierarchy governing RhIG management in US hospitals.<br>
                Sources: FDA, AABB, CAP, Joint Commission
              </figcaption>
            </figure>
          </div>
        </div>

        <!-- Detail Panels -->
        <div class="detail-panel" id="panel-fda">
          <button class="close-btn" onclick="closePanel()">√ó</button>
          <h3>FDA / CBER Regulation</h3>
          <p>RhIG is regulated by the Center for Biologics Evaluation and Research (CBER) under <strong>21 CFR Part 640 Subpart J</strong> - Immune Globulin (Human).</p>
          <p>This classifies RhIG as a <strong>plasma derivative</strong>, NOT a blood component under Part 606.</p>
          <div class="key-point">
            <strong>Key Point:</strong> Storage at 2-8¬∞C required. Never expose above 45¬∞C during processing.
          </div>
        </div>

        <div class="detail-panel" id="panel-aabb">
          <button class="close-btn" onclick="closePanel()">√ó</button>
          <h3>AABB Standards</h3>
          <p><strong>Standard 5.30:</strong> "The transfusion service SHALL have a policy for Rh Immune Globulin prophylaxis."</p>
          <p><strong>Standard 5.30.2:</strong> Requires D antigen testing before administration.</p>
          <p><strong>Standard 5.30.3:</strong> Ensures appropriate dosing.</p>
          <div class="key-point">
            <strong>Key Point:</strong> The word "SHALL" makes this a mandatory requirement for AABB-accredited facilities. The transfusion service, not pharmacy, is explicitly responsible.
          </div>
        </div>

        <div class="detail-panel" id="panel-cap">
          <button class="close-btn" onclick="closePanel()">√ó</button>
          <h3>College of American Pathologists</h3>
          <p>CAP's Transfusion Medicine (TRM) Checklist includes requirements for RhIG testing and administration.</p>
          <p>Surveys focus on laboratory procedures including weak D testing and FMH quantification.</p>
          <div class="key-point">
            <strong>Key Point:</strong> CAP checklist TRM.40780 addresses weak D testing requirements for newborns.
          </div>
        </div>

        <div class="detail-panel" id="panel-jc">
          <button class="close-btn" onclick="closePanel()">√ó</button>
          <h3>Joint Commission</h3>
          <p>JC classifies RhIG as a "blood derivative" which can be surveyed under:</p>
          <p>‚Ä¢ <strong>Immunohematology Standards</strong> (Blood Bank), OR<br>‚Ä¢ <strong>Medication Management Standards</strong> (Pharmacy)</p>
          <div class="key-point">
            <strong>Key Point:</strong> Official JC position: "No, this is NOT a mandatory practice" - either approach is acceptable. Some surveyors have incorrectly stated pharmacy is required.
          </div>
        </div>

        <div class="detail-panel" id="panel-state">
          <button class="close-btn" onclick="closePanel()">√ó</button>
          <h3>State Regulations</h3>
          <p>State requirements vary significantly by jurisdiction.</p>
          <p>Some state pharmacy boards may require oversight of all medications including blood derivatives.</p>
          <div class="key-point">
            <strong>Key Point:</strong> Check your specific state's pharmacy board and health department requirements for guidance.
          </div>
        </div>

        <div class="detail-panel" id="panel-hospital">
          <button class="close-btn" onclick="closePanel()">√ó</button>
          <h3>Hospital Policies</h3>
          <p>Institutions have flexibility in determining whether blood bank or pharmacy manages RhIG inventory.</p>
          <p><strong>Recommended:</strong> Blood bank management with Type & Screen verification before dispensing.</p>
          <div class="key-point">
            <strong>Key Point:</strong> Regardless of storage location, Type and Screen must be completed before release, and blood bank should verify patient eligibility.
          </div>
        </div>

        <h3 id="aabb">AABB Standards: Clear Assignment to Transfusion Service</h3>

        <p>The AABB (formerly American Association of Blood Banks) Standards for Blood Banks and Transfusion Services provide the most explicit guidance on institutional responsibility:</p>

        <div class="key-point">
          <h4>AABB Standards for RhIG</h4>
          <p><strong>Standard 5.30:</strong> "The transfusion service <strong>SHALL</strong> have a policy for Rh Immune Globulin prophylaxis."<br><br>
          <strong>Standard 5.30.2:</strong> Requires testing for D antigen before RhIG administration.<br><br>
          <strong>Standard 5.30.3:</strong> "The transfusion service shall ensure that the appropriate dose of Rh Immune Globulin is administered."</p>
        </div>

        <p>These standards use mandatory language ("shall") and explicitly assign policy responsibility to the transfusion service‚Äînot the pharmacy. Notably, a recent survey found that approximately 50% of US AABB-accredited institutions may not have comprehensive RhIG policies, suggesting significant compliance gaps.</p>

        <h3 id="jc">Joint Commission: The Source of Confusion</h3>

        <p>The Joint Commission classifies RhIG as a "blood derivative," which by their definition places it in the category of "medications." This classification has led some surveyors to state that RhoGAM must be under pharmacy control.</p>

        <p>However, the official Joint Commission position, clarified by representative Megan Sawchuk, is unambiguous:</p>

        <blockquote>
          <p>"No, this is NOT a mandatory practice. Rho Immune Globulin is a 'blood derivative'... [JC] surveys these products under EITHER Immunohematology standards OR Medication Management standards."</p>
          <cite>‚Äî Megan Sawchuk, Joint Commission</cite>
        </blockquote>

        <p>This means hospitals have flexibility in their approach, and neither blood bank nor pharmacy management is mandated by the Joint Commission. The organization will survey RhIG management under whichever departmental standards apply based on institutional policy.</p>

        <h2 id="blood-bank-case">The Case for Blood Bank Management</h2>

        <h3 id="testing">Critical Testing Requirements</h3>

        <p>The strongest argument for blood bank management centers on the <strong>mandatory testing that must occur before RhIG dispensing</strong>. Unlike most medications, RhIG requires laboratory verification before administration:</p>

        <ol>
          <li><strong>Type and Screen:</strong> Must confirm the mother is Rh-negative</li>
          <li><strong>Antibody Screening:</strong> Must verify the patient is not already sensitized (has not formed anti-D)</li>
          <li><strong>Cord Blood Testing:</strong> For postpartum administration, must confirm the infant is Rh-positive</li>
          <li><strong>FMH Testing:</strong> For postpartum patients, may require fetal-maternal hemorrhage quantification</li>
        </ol>

        <!-- Workflow Visualization -->
        <div class="viz-section">
          <div class="viz-embed">
            <figure id="viz-3">
              <div class="viz-header" style="text-align: center; margin-bottom: 32px;">
                <h1 style="font-size: 1.75rem; color: #1e3a5f; margin-bottom: 8px;">RhIG Administration Workflow</h1>
                <p style="color: #64748b; font-size: 0.95rem;">Complete process from order to documentation</p>
              </div>

              <div class="flowchart">
                <div class="flow-step clinical">
                  <div class="step-number">1</div>
                  <div class="step-box">
                    <span class="dept-badge">Clinical</span>
                    <h3>Order Placed for RhIG</h3>
                    <p>Provider orders RhIG for eligible patient</p>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="flow-step bloodbank">
                  <div class="step-number">2</div>
                  <div class="step-box">
                    <span class="dept-badge">Blood Bank</span>
                    <h3>Type and Screen Performed</h3>
                    <p>Maternal blood sample tested for ABO/Rh type and antibodies</p>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="decision-box">
                  <div class="decision">
                    <h3>Is mother Rh-negative?</h3>
                  </div>
                  <div class="decision-branches">
                    <div class="branch branch-no">
                      <div class="branch-label">No</div>
                      <div class="branch-arrow"></div>
                      <div style="font-size: 0.8rem; color: #991b1b;">Not eligible</div>
                    </div>
                    <div class="branch branch-yes">
                      <div class="branch-label">Yes</div>
                      <div class="branch-arrow"></div>
                      <div style="font-size: 0.8rem; color: #166534;">Continue</div>
                    </div>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="flow-step bloodbank">
                  <div class="step-number">3</div>
                  <div class="step-box">
                    <span class="dept-badge">Blood Bank</span>
                    <h3>Check Antibody Screen</h3>
                    <p>Verify no existing anti-D (patient not already sensitized)</p>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="flow-step bloodbank">
                  <div class="step-number">4</div>
                  <div class="step-box">
                    <span class="dept-badge">Blood Bank</span>
                    <h3>Cord Blood Testing (Postpartum)</h3>
                    <p>Test infant's blood type to confirm Rh-positive status</p>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="flow-step bloodbank">
                  <div class="step-number">5</div>
                  <div class="step-box">
                    <span class="dept-badge">Blood Bank</span>
                    <h3>FMH Screening (Rosette Test)</h3>
                    <p>Screen for fetomaternal hemorrhage > 30mL</p>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="flow-step bloodbank">
                  <div class="step-number">6</div>
                  <div class="step-box">
                    <span class="dept-badge">Blood Bank</span>
                    <h3>Calculate & Dispense Dose</h3>
                    <p>Dispense appropriate number of vials based on testing</p>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="flow-step nursing">
                  <div class="step-number">7</div>
                  <div class="step-box">
                    <span class="dept-badge">Nursing</span>
                    <h3>Verify Patient Identity</h3>
                    <p>Two-person verification at bedside</p>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="flow-step nursing">
                  <div class="step-number">8</div>
                  <div class="step-box">
                    <span class="dept-badge">Nursing</span>
                    <h3>Administer Within 72 Hours</h3>
                    <p>IM injection; monitor for reactions</p>
                  </div>
                </div>

                <div class="arrow"></div>

                <div class="flow-step bloodbank">
                  <div class="step-number">9</div>
                  <div class="step-box">
                    <span class="dept-badge">Blood Bank</span>
                    <h3>Document Lot Number</h3>
                    <p>Record administration for traceability</p>
                  </div>
                </div>
              </div>

              <div class="critical-note">
                <svg viewBox="0 0 24 24"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z"/></svg>
                <p><strong>Critical:</strong> Type and Screen MUST be completed before RhIG release. This is a core blood bank safety checkpoint.</p>
              </div>

              <div class="legend">
                <div class="legend-item"><div class="legend-dot" style="background: #6366f1; width: 16px; height: 16px; border-radius: 4px;"></div><span>Clinical/Provider</span></div>
                <div class="legend-item"><div class="legend-dot" style="background: #dc2626; width: 16px; height: 16px; border-radius: 4px;"></div><span>Blood Bank</span></div>
                <div class="legend-item"><div class="legend-dot" style="background: #059669; width: 16px; height: 16px; border-radius: 4px;"></div><span>Nursing</span></div>
              </div>

              <figcaption class="viz-source">
                <strong>Figure 3:</strong> Complete RhIG administration workflow showing blood bank's central role.<br>
                Sources: AABB Standards, UTMB Policy, Institutional Guidelines
              </figcaption>
            </figure>
          </div>
        </div>

        <p>The blood bank performs all of these tests. When RhIG is stored in the pharmacy, there is an inherent disconnect: pharmacists must rely on communication from the blood bank about test results, or clinicians may attempt to order RhIG before testing is complete.</p>

        <h3 id="dosing">Dosing Expertise: More Complex Than Standard Medications</h3>

        <p>For most postpartum administrations, a single 300-microgram dose is sufficient. However, when fetomaternal hemorrhage exceeds 30 mL of whole blood, additional doses are required. The blood bank possesses unique expertise in:</p>

        <ul>
          <li><strong>Rosette Testing:</strong> Screening for significant FMH (>10 mL)</li>
          <li><strong>Kleihauer-Betke Testing:</strong> Quantifying fetal hemoglobin in maternal blood</li>
          <li><strong>Flow Cytometry:</strong> More accurate FMH quantification</li>
          <li><strong>Dose Calculation:</strong> Using the formula (% HbF √ó 5000)/30 + 1 = number of vials</li>
        </ul>

        <p>These calculations are not straightforward pharmaceutical dosing‚Äîthey require interpretation of specialized laboratory tests that only transfusion medicine professionals routinely perform.</p>

        <h3 id="safety">Patient Safety Data: Evidence of Risk</h3>

        <p>Real-world safety data supports blood bank management. A study examining 29,801 deliveries across two major health systems found that <strong>17 eligible patients missed their RhIG doses</strong>, representing a 0.8% miss rate. Root cause analysis identified:</p>

        <!-- Missed Doses Visualization -->
        <div class="viz-section">
          <div class="viz-embed">
            <figure id="viz-4">
              <div class="viz-header" style="text-align: center; margin-bottom: 24px;">
                <h1 style="font-size: 1.75rem; color: #1e3a5f; margin-bottom: 8px;">Why RhIG Doses Are Missed</h1>
                <p style="color: #64748b; font-size: 0.95rem;">Root cause analysis from study of 29,801 deliveries across two health systems</p>
              </div>

              <div class="stats-row">
                <div class="stat-card">
                  <div class="stat-value">29,801</div>
                  <div class="stat-label">Total Deliveries Studied</div>
                </div>
                <div class="stat-card">
                  <div class="stat-value highlight">17</div>
                  <div class="stat-label">Missed RhIG Doses</div>
                </div>
                <div class="stat-card">
                  <div class="stat-value success">99.2%</div>
                  <div class="stat-label">Prophylaxis Rate</div>
                </div>
              </div>

              <div class="chart-wrapper">
                <canvas id="missedDosesChart"></canvas>
              </div>

              <div class="insights">
                <h3>Key Insights for Prevention</h3>
                <ul>
                  <li><strong>Missing Orders:</strong> Orders never placed due to amended infant blood type results or documentation gaps</li>
                  <li><strong>Communication Barriers:</strong> Patient factors (limited English, hearing impairment) contributed to missed doses</li>
                  <li><strong>Documentation Gaps:</strong> Providers manually verifying multiple data sources - neonatal labs, MAR, postpartum notes</li>
                  <li><strong>Workflow Complexity:</strong> Average 27+ seconds required to look up and document all required information</li>
                </ul>
              </div>

              <div class="success-note">
                <svg viewBox="0 0 24 24"><path d="M9 16.17L4.83 12l-1.42 1.41L9 19 21 7l-1.41-1.41L9 16.17z"/></svg>
                <p><strong>Solution:</strong> Implementation of an EHR toolkit with automated documentation and decision-support alerts achieved <strong>100% administration rate</strong> - zero additional missed doses after implementation.</p>
              </div>

              <figcaption class="viz-source">
                <strong>Figure 4:</strong> Distribution of root causes for missed RhIG administration.<br>
                Source: PMC9563491 - Missed anti-D immune globulin administration study
              </figcaption>
            </figure>
          </div>
        </div>

        <p>Critically, when blood bank oversight was bypassed or communication between departments failed, errors occurred. The implementation of an Electronic Health Record toolkit with blood bank integration achieved a <strong>100% administration rate</strong>‚Äîeliminating missed doses entirely.</p>

        <p>Professional forums document additional safety concerns when pharmacy holds RhIG stock:</p>

        <ul>
          <li>ED and OR staff ordering without completed Type and Screen</li>
          <li>Clinicians bypassing established protocols</li>
          <li>Duplicate administration due to lack of integrated tracking</li>
          <li>Inappropriate dosing without FMH testing</li>
        </ul>

        <h2 id="pharmacy-case">The Case for Pharmacy Management</h2>

        <p>Proponents of pharmacy management cite RhIG's classification:</p>

        <ul>
          <li><strong>Blood Derivative:</strong> Manufactured through plasma fractionation, similar to IVIG and albumin</li>
          <li><strong>Medication Definition:</strong> Falls under Joint Commission medication management standards</li>
          <li><strong>Consistency:</strong> Other plasma derivatives (clotting factors, IVIG) are typically managed by pharmacy</li>
        </ul>

        <p>Some institutions cite operational advantages of pharmacy management:</p>

        <ul>
          <li><strong>24/7 Staffing:</strong> Pharmacy may have more consistent overnight coverage</li>
          <li><strong>Inventory Systems:</strong> Integration with hospital medication dispensing systems</li>
          <li><strong>Workload Distribution:</strong> May reduce blood bank staffing burden</li>
          <li><strong>State Requirements:</strong> Some state pharmacy boards may require oversight of all medications</li>
        </ul>

        <!-- Comparison Visualization -->
        <div class="viz-section">
          <div class="viz-embed">
            <figure id="viz-5">
              <div class="viz-header" style="text-align: center; margin-bottom: 32px;">
                <h1 style="font-size: 1.75rem; color: #1e3a5f; margin-bottom: 8px;">Blood Bank vs Pharmacy: Side-by-Side Comparison</h1>
                <p style="color: #64748b; font-size: 0.95rem;">Evaluating key criteria for RhIG management</p>
              </div>

              <table class="comparison-table">
                <thead>
                  <tr>
                    <th>Criterion</th>
                    <th class="bloodbank">Blood Bank</th>
                    <th class="pharmacy">Pharmacy</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>Testing Access</td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Direct access to Type & Screen, cord blood, and FMH testing</span></div></td>
                    <td><div class="rating"><span class="rating-icon limited">-</span><span>Dependent on communication from blood bank</span></div></td>
                  </tr>
                  <tr>
                    <td>Dosing Expertise</td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Native expertise in FMH calculation and dose determination</span></div></td>
                    <td><div class="rating"><span class="rating-icon limited">-</span><span>Requires consultation with blood bank for complex cases</span></div></td>
                  </tr>
                  <tr>
                    <td>AABB Compliance</td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Explicit requirement in Standard 5.30</span></div></td>
                    <td><div class="rating"><span class="rating-icon good">~</span><span>Requires additional coordination to meet standards</span></div></td>
                  </tr>
                  <tr>
                    <td>JC Compliance</td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Surveyed under Immunohematology standards</span></div></td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Surveyed under Medication Management standards</span></div></td>
                  </tr>
                  <tr>
                    <td>Traceability</td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Integrated with transfusion medicine records</span></div></td>
                    <td><div class="rating"><span class="rating-icon good">~</span><span>Separate medication tracking system</span></div></td>
                  </tr>
                  <tr>
                    <td>Safety Checkpoints</td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Mandatory verification before release</span></div></td>
                    <td><div class="rating"><span class="rating-icon limited">-</span><span>Risk of bypassing testing if not well-controlled</span></div></td>
                  </tr>
                  <tr>
                    <td>24/7 Availability</td>
                    <td><div class="rating"><span class="rating-icon good">~</span><span>Variable by institution; may have limited off-hours staffing</span></div></td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Often robust 24/7 coverage</span></div></td>
                  </tr>
                  <tr>
                    <td>Inventory Systems</td>
                    <td><div class="rating"><span class="rating-icon good">~</span><span>Blood product-focused systems</span></div></td>
                    <td><div class="rating"><span class="rating-icon excellent">+</span><span>Robust medication inventory management</span></div></td>
                  </tr>
                </tbody>
              </table>

              <div class="verdict">
                <div class="verdict-card bloodbank">
                  <h3>Blood Bank Management</h3>
                  <div class="score">6/8</div>
                  <p>Excellent on safety-critical criteria: testing, dosing, safety checkpoints</p>
                </div>
                <div class="verdict-card pharmacy">
                  <h3>Pharmacy Management</h3>
                  <div class="score">4/8</div>
                  <p>Strong on operational criteria but gaps in clinical oversight</p>
                </div>
              </div>

              <div class="recommendation">
                <svg viewBox="0 0 24 24"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm-2 15l-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8l-9 9z"/></svg>
                <div class="recommendation-text">
                  <h4>Evidence-Based Recommendation</h4>
                  <p>Blood bank management is preferred due to superior performance on safety-critical criteria. The AABB explicitly requires transfusion service policy, and blood bank provides direct access to required testing. If pharmacy management is chosen, formal blood bank verification before dispensing is essential.</p>
                </div>
              </div>

              <figcaption class="viz-source">
                <strong>Figure 5:</strong> Comparison of blood bank vs pharmacy management across key criteria.<br>
                Source: Research synthesis from AABB Standards, Joint Commission, and peer-reviewed literature
              </figcaption>
            </figure>
          </div>
        </div>

        <h2 id="hybrid">The Recommended Approach: The Hybrid Model</h2>

        <p>Based on the evidence, the optimal approach combines blood bank clinical oversight with institutional flexibility:</p>

        <h3>Core Principles</h3>

        <ol>
          <li><strong>Blood Bank Controls Clinical Decision-Making</strong>
            <ul>
              <li>All testing (Type and Screen, cord blood, FMH) performed by blood bank</li>
              <li>Eligibility verification by blood bank staff</li>
              <li>Dose calculations for large FMH by blood bank</li>
              <li>Documentation on standardized control forms</li>
            </ul>
          </li>
          <li><strong>Flexible Dispensing Options</strong>
            <ul>
              <li><strong>Option A</strong> (Recommended): Blood bank stores and dispenses directly</li>
              <li><strong>Option B</strong>: Pharmacy dispenses ONLY upon receiving completed blood bank verification forms</li>
            </ul>
          </li>
          <li><strong>Non-Negotiable Safety Checkpoints</strong>
            <ul>
              <li>NO RhIG released without completed Type and Screen</li>
              <li>Verification of Rh-negative maternal status</li>
              <li>Confirmation of Rh-positive infant (for postpartum administration)</li>
              <li>Review for existing anti-D antibodies</li>
              <li>FMH testing for all postpartum patients</li>
            </ul>
          </li>
        </ol>

        <!-- Decision Tree Visualization -->
        <div class="viz-section">
          <div class="viz-embed">
            <figure id="viz-6">
              <div class="viz-header" style="text-align: center; margin-bottom: 32px;">
                <h1 style="font-size: 1.75rem; color: #1e3a5f; margin-bottom: 8px;">RhIG Patient Eligibility Decision Tree</h1>
                <p style="color: #64748b; font-size: 0.95rem;">Step-by-step determination of RhIG candidacy</p>
              </div>

              <div class="decision-tree">
                <div class="node">
                  <div class="question-node">
                    <h3>Is the patient Rh-negative?</h3>
                    <p>Based on Type and Screen results</p>
                  </div>
                </div>

                <div class="branches">
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label no">NO</div>
                    <div class="outcome-node stop">NOT ELIGIBLE<br><small>Rh-positive patients do not need RhIG</small></div>
                  </div>
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label yes">YES</div>
                    <div class="connector"></div>
                  </div>
                </div>

                <div class="node" style="margin-top: -8px;">
                  <div class="question-node">
                    <h3>Does patient have existing anti-D?</h3>
                    <p>Check antibody screen results</p>
                  </div>
                </div>

                <div class="branches">
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label yes">YES</div>
                    <div class="outcome-node stop">NOT ELIGIBLE<br><small>Already sensitized; RhIG cannot help</small></div>
                  </div>
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label no">NO</div>
                    <div class="connector"></div>
                  </div>
                </div>

                <div class="node" style="margin-top: -8px;">
                  <div class="question-node">
                    <h3>Is this antepartum or postpartum?</h3>
                    <p>Timing determines testing requirements</p>
                  </div>
                </div>

                <div class="branches">
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label" style="background: #e0e7ff; color: #4338ca;">ANTEPARTUM</div>
                    <div class="outcome-node action">ADMINISTER at 28 weeks<br><small>Standard 300 mcg dose</small></div>
                  </div>
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label" style="background: #fce7f3; color: #9d174d;">POSTPARTUM</div>
                    <div class="connector"></div>
                  </div>
                </div>

                <div class="node" style="margin-top: -8px;">
                  <div class="question-node">
                    <h3>Is the infant Rh-positive?</h3>
                    <p>Based on cord blood testing</p>
                  </div>
                </div>

                <div class="branches">
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label no">NO</div>
                    <div class="outcome-node stop">NOT NEEDED<br><small>Rh-negative infant poses no risk</small></div>
                  </div>
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label yes">YES</div>
                    <div class="connector"></div>
                  </div>
                </div>

                <div class="node" style="margin-top: -8px;">
                  <div class="question-node">
                    <h3>Is FMH greater than 30mL?</h3>
                    <p>Rosette test screening</p>
                  </div>
                </div>

                <div class="branches">
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label no">NO</div>
                    <div class="outcome-node action">STANDARD DOSE<br><small>One 300 mcg vial</small></div>
                  </div>
                  <div class="branch">
                    <div class="branch-line"></div>
                    <div class="branch-label yes">YES</div>
                    <div class="outcome-node action">CALCULATE DOSE<br><small>KB test ‚Üí Formula:<br>(% HbF √ó 5000)/30 + 1</small></div>
                  </div>
                </div>
              </div>

              <div class="legend" style="padding-top: 24px; border-top: 1px solid #e2e8f0;">
                <div class="legend-item"><div class="legend-box question"></div><span>Decision Point</span></div>
                <div class="legend-item"><div class="legend-box stop"></div><span>Not Eligible / Not Needed</span></div>
                <div class="legend-item"><div class="legend-box action"></div><span>Administer RhIG</span></div>
              </div>

              <figcaption class="viz-source">
                <strong>Figure 6:</strong> Decision tree for determining RhIG candidacy and dosing.<br>
                Sources: ACOG Practice Bulletin, AABB Standards
              </figcaption>
            </figure>
          </div>
        </div>

        <h2 id="products">Available RhIG Products</h2>

        <!-- Products Visualization -->
        <div class="viz-section">
          <div class="viz-embed">
            <figure id="viz-7">
              <div class="viz-header" style="text-align: center; margin-bottom: 32px;">
                <h1 style="font-size: 1.75rem; color: #1e3a5f; margin-bottom: 8px;">FDA-Licensed RhIG Products</h1>
                <p style="color: #64748b; font-size: 0.95rem;">Available products in the United States for Rh immunoprophylaxis</p>
              </div>

              <div class="products-grid">
                <div class="product-card standard-dose">
                  <div class="product-header">
                    <div class="product-name">RhoGAM Ultra-Filtered PLUS</div>
                    <span class="product-badge standard">Standard</span>
                  </div>
                  <div class="product-manufacturer">Kedrion Biopharma Inc.</div>
                  <div class="product-details">
                    <div class="detail-item"><div class="detail-label">Dose</div><div class="detail-value">300 mcg</div></div>
                    <div class="detail-item"><div class="detail-label">Route</div><div class="detail-value">IM only</div></div>
                  </div>
                  <div class="product-notes">Most commonly used product in US hospitals. Ultra-filtered for enhanced purity.</div>
                </div>

                <div class="product-card mini-dose">
                  <div class="product-header">
                    <div class="product-name">MICRhoGAM</div>
                    <span class="product-badge mini">Mini-Dose</span>
                  </div>
                  <div class="product-manufacturer">Kedrion Biopharma Inc.</div>
                  <div class="product-details">
                    <div class="detail-item"><div class="detail-label">Dose</div><div class="detail-value">50 mcg</div></div>
                    <div class="detail-item"><div class="detail-label">Route</div><div class="detail-value">IM only</div></div>
                  </div>
                  <div class="product-notes">For early pregnancy events <12 weeks gestation.</div>
                </div>

                <div class="product-card standard-dose">
                  <div class="product-header">
                    <div class="product-name">WinRho SDF</div>
                    <span class="product-badge iv-capable">IV/IM</span>
                  </div>
                  <div class="product-manufacturer">Kamada Ltd.</div>
                  <div class="product-details">
                    <div class="detail-item"><div class="detail-label">Dose</div><div class="detail-value">Variable</div></div>
                    <div class="detail-item"><div class="detail-label">Route</div><div class="detail-value">IV or IM</div></div>
                  </div>
                  <div class="product-notes">Also FDA-approved for immune thrombocytopenic purpura (ITP).</div>
                </div>

                <div class="product-card standard-dose">
                  <div class="product-header">
                    <div class="product-name">Rhophylac</div>
                    <span class="product-badge iv-capable">IV/IM</span>
                  </div>
                  <div class="product-manufacturer">CSL Behring AG</div>
                  <div class="product-details">
                    <div class="detail-item"><div class="detail-label">Dose</div><div class="detail-value">300 mcg</div></div>
                    <div class="detail-item"><div class="detail-label">Route</div><div class="detail-value">IV or IM</div></div>
                  </div>
                  <div class="product-notes">IV option allows for faster administration. Pre-filled syringe available.</div>
                </div>

                <div class="product-card standard-dose">
                  <div class="product-header">
                    <div class="product-name">HyperRHO S/D Full</div>
                    <span class="product-badge standard">Standard</span>
                  </div>
                  <div class="product-manufacturer">Grifols Therapeutics LLC</div>
                  <div class="product-details">
                    <div class="detail-item"><div class="detail-label">Dose</div><div class="detail-value">300 mcg</div></div>
                    <div class="detail-item"><div class="detail-label">Route</div><div class="detail-value">IM only</div></div>
                  </div>
                  <div class="product-notes">Solvent/detergent treated for viral inactivation.</div>
                </div>

                <div class="product-card mini-dose">
                  <div class="product-header">
                    <div class="product-name">HyperRHO S/D Mini</div>
                    <span class="product-badge mini">Mini-Dose</span>
                  </div>
                  <div class="product-manufacturer">Grifols Therapeutics LLC</div>
                  <div class="product-details">
                    <div class="detail-item"><div class="detail-label">Dose</div><div class="detail-value">50 mcg</div></div>
                    <div class="detail-item"><div class="detail-label">Route</div><div class="detail-value">IM only</div></div>
                  </div>
                  <div class="product-notes">Alternative mini-dose option for early pregnancy events.</div>
                </div>
              </div>

              <div class="info-box">
                <h3>Interchangeability</h3>
                <p>All FDA-licensed RhIG products are considered interchangeable for prophylaxis purposes. During shortages, institutions should be prepared to substitute available products. Consult AABB Association Bulletin #24-02 for shortage management guidance.</p>
              </div>

              <div class="dosing-note">
                <h3>Standard Dosing Reference</h3>
                <table class="dosing-table">
                  <tr>
                    <th>Indication</th>
                    <th>Dose</th>
                    <th>Coverage</th>
                  </tr>
                  <tr>
                    <td>Antepartum (28 weeks)</td>
                    <td>300 mcg</td>
                    <td>Protects for ~12 weeks</td>
                  </tr>
                  <tr>
                    <td>Postpartum (within 72 hrs)</td>
                    <td>300 mcg*</td>
                    <td>Covers up to 30 mL fetal blood</td>
                  </tr>
                  <tr>
                    <td>Early pregnancy (<12 weeks)</td>
                    <td>50-300 mcg</td>
                    <td>See current ACOG guidance</td>
                  </tr>
                </table>
                <p style="font-size: 0.8rem; color: #64748b; margin-top: 12px;">*Additional doses may be required if FMH exceeds 30 mL</p>
              </div>

              <figcaption class="viz-source">
                <strong>Figure 7:</strong> FDA-licensed RhIG products available in the United States.<br>
                Source: AABB Association Bulletin #24-02; FDA Approved Blood Products
              </figcaption>
            </figure>
          </div>
        </div>

        <p>All FDA-licensed RhIG products are considered interchangeable for prophylaxis purposes, though some have additional indications (such as WinRho for immune thrombocytopenic purpura). During shortages, institutions should be prepared to substitute available products as needed.</p>

        <div class="takeaways" id="takeaways">
          <h2>Key Takeaways</h2>
          <ul>
            <li><strong>AABB Standards explicitly require</strong> the transfusion service to maintain RhIG policies‚Äîthis is not optional for accredited blood banks</li>
            <li><strong>Type and Screen verification</strong> must occur before RhIG dispensing, making blood bank involvement essential regardless of storage location</li>
            <li><strong>The Joint Commission does NOT mandate</strong> either blood bank or pharmacy management‚Äîinstitutions have flexibility</li>
            <li><strong>Patient safety data</strong> demonstrates risks when blood bank oversight is bypassed</li>
            <li><strong>A hybrid model</strong> with blood bank clinical control and flexible dispensing offers the best balance of safety and operational efficiency</li>
            <li><strong>Missed RhIG prophylaxis</strong> should be treated as a "never event" given the potential for devastating consequences</li>
          </ul>
        </div>

        <h2 id="conclusion">Conclusion</h2>

        <p>The question of whether RhoGAM should be housed in the blood bank or pharmacy is ultimately a question of patient safety. While regulatory frameworks allow institutional flexibility, the scientific evidence strongly supports <strong>blood bank management</strong> as the safer and more effective approach.</p>

        <p>The AABB Standards are explicit: the transfusion service "shall" have a policy for RhIG prophylaxis and "shall ensure" appropriate dosing. The mandatory testing requirements‚ÄîType and Screen, antibody screening, cord blood typing, and FMH quantification‚Äîare core blood bank functions. Patient safety data shows that bypassing blood bank oversight leads to errors.</p>

        <p>The Joint Commission's classification of RhIG as a "blood derivative" does not mandate pharmacy management‚Äîit simply means institutions can choose their approach. But choosing should be guided by evidence, not administrative convenience.</p>

        <p>For healthcare professionals, hospital administrators, and accreditation surveyors, the message is clear: <strong>RhIG is safest when managed by the blood bank</strong>, with appropriate policies, testing protocols, and documentation systems in place. The 10,000 lives saved annually by RhIG depend on getting this right.</p>

        <blockquote>
          <p>"Pharmacists can play an essential role in ensuring the safe administration of these products by guiding clinicians on the use and timing of RhIG therapy."</p>
          <cite>‚Äî NCBI StatPearls</cite>
        </blockquote>

        <p>This statement acknowledges the pharmacist's role‚Äîbut note that it speaks to "guiding clinicians," not to physically storing and dispensing the product. The collaborative model, with blood bank oversight and interdisciplinary support, represents the evidence-based best practice for RhIG management.</p>

        <section class="sources-section" id="sources">
          <h2>Sources</h2>
          <div class="sources-grid">
            <div class="source-item"><span class="source-num">1</span><a href="https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/rhogam-micrhogam" target="_blank">FDA - RhoGAM & MICRhoGAM</a></div>
            <div class="source-item"><span class="source-num">2</span><a href="https://www.aabb.org/standards-accreditation/standards/blood-banks-and-transfusion-services" target="_blank">AABB - Standards for Blood Banks and Transfusion Services</a></div>
            <div class="source-item"><span class="source-num">3</span><a href="https://www.aabb.org/docs/default-source/default-document-library/standards/proposed-35th-edition-of-standards-for-blood-banks-and-transfusion-services.pdf" target="_blank">AABB - Proposed Standards 35th Edition</a></div>
            <div class="source-item"><span class="source-num">4</span><a href="https://www.aabb.org/docs/default-source/default-document-library/resources/association-bulletins/ab24-02.pdf" target="_blank">AABB - Association Bulletin #24-02</a></div>
            <div class="source-item"><span class="source-num">5</span><a href="https://www.ncbi.nlm.nih.gov/books/NBK557884/" target="_blank">NCBI - Rho(D) Immune Globulin StatPearls</a></div>
            <div class="source-item"><span class="source-num">6</span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9563491/" target="_blank">PMC - Missed anti-D immune globulin administration study</a></div>
            <div class="source-item"><span class="source-num">7</span><a href="https://www.pathlabtalk.com/forum/topic/4804-rhogamrhophylac-must-be-under-pharmacy-control/" target="_blank">PathLabTalk - RhoGAM/RhoPhylac pharmacy control discussion</a></div>
            <div class="source-item"><span class="source-num">8</span><a href="https://www.utmb.edu/lsg2/Home/Details?id=916" target="_blank">UTMB - Rh Immune Globulin Policy</a></div>
            <div class="source-item"><span class="source-num">9</span><a href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-640/subpart-J" target="_blank">eCFR - 21 CFR Part 640 Subpart J</a></div>
            <div class="source-item"><span class="source-num">10</span><a href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-606" target="_blank">eCFR - 21 CFR Part 606</a></div>
            <div class="source-item"><span class="source-num">11</span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5757578/" target="_blank">PMC - ISBT 128 Standard</a></div>
            <div class="source-item"><span class="source-num">12</span><a href="https://www.isbtweb.org/resource/tb-004-isbt-128-and-traceability-v1-1-0-pdf.html" target="_blank">ISBT - Traceability Technical Bulletin</a></div>
            <div class="source-item"><span class="source-num">13</span><a href="https://www.ncbi.nlm.nih.gov/books/NBK430876/" target="_blank">NCBI - Kleihauer Betke Test StatPearls</a></div>
            <div class="source-item"><span class="source-num">14</span><a href="https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2024/03/rhod-immune-globulin-shortages" target="_blank">ACOG - Rho(D) Immune Globulin Shortages</a></div>
            <div class="source-item"><span class="source-num">15</span><a href="https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/08/prevention-of-rh-d-alloimmunization" target="_blank">ACOG - Prevention of Rh D Alloimmunization</a></div>
            <div class="source-item"><span class="source-num">16</span><a href="https://www.kedrion.us/licenses-for-rhogam-and-micrhogam-transferred-to-kedrion/" target="_blank">Kedrion Biopharma - License acquisition</a></div>
            <div class="source-item"><span class="source-num">17</span><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d87e4d0b-2442-4135-b3f9-5c4f74845b87" target="_blank">DailyMed - RhoGAM Prescribing Information</a></div>
            <div class="source-item"><span class="source-num">18</span><a href="https://en.wikipedia.org/wiki/Rho(D)_immune_globulin" target="_blank">Wikipedia - Rho(D) immune globulin</a></div>
            <div class="source-item"><span class="source-num">19</span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9824959/" target="_blank">PMC - Hemolytic disease of the fetus and newborn systematic review</a></div>
            <div class="source-item"><span class="source-num">20</span><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235807" target="_blank">PLOS ONE - HDFN due to Rh(D) incompatibility</a></div>
            <div class="source-item"><span class="source-num">21</span><a href="https://link.springer.com/article/10.1007/s00431-022-04724-0" target="_blank">Springer - History of postnatal management in HDFN</a></div>
            <div class="source-item"><span class="source-num">22</span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5612847/" target="_blank">PMC - Serological weak D phenotypes review</a></div>
            <div class="source-item"><span class="source-num">23</span><a href="https://www.ncbi.nlm.nih.gov/books/NBK557423/" target="_blank">NCBI - Hemolytic Disease of the Fetus and Newborn StatPearls</a></div>
            <div class="source-item"><span class="source-num">24</span><a href="https://www.ncbi.nlm.nih.gov/books/NBK560488/" target="_blank">NCBI - Rh Hemolytic Disease StatPearls</a></div>
            <div class="source-item"><span class="source-num">25</span><a href="https://www.jointcommission.org/standards/standard-faqs/critical-access-hospital/provision-of-care-treatment-and-services-pc/000001569/" target="_blank">Joint Commission - Transfusion Administration Standards FAQ</a></div>
            <div class="source-item"><span class="source-num">26</span><a href="https://www.pathology.med.umich.edu/blood-bank/general-information" target="_blank">University of Michigan - Transfusion Medicine</a></div>
            <div class="source-item"><span class="source-num">27</span><a href="https://pubmed.ncbi.nlm.nih.gov/38534065/" target="_blank">PubMed - RhIG immunoprophylaxis survey</a></div>
            <div class="source-item"><span class="source-num">28</span><a href="https://pubmed.ncbi.nlm.nih.gov/24786120/" target="_blank">PubMed - CAP weak D testing policies survey</a></div>
            <div class="source-item"><span class="source-num">29</span><a href="https://www.redcross.org/content/dam/redcrossblood/hospital-page-documents/334401_compendium_v04jan2021_bookmarkedworking_rwv01.pdf" target="_blank">Red Cross - Compendium of Transfusion Practice Guidelines</a></div>
            <div class="source-item"><span class="source-num">30</span><a href="https://emedicine.medscape.com/article/974349-overview" target="_blank">Emedicine/Medscape - Hemolytic Disease of the Newborn</a></div>
            <div class="source-item"><span class="source-num">31</span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7365158/" target="_blank">PMC - Approach to RBC antibody testing during pregnancy</a></div>
            <div class="source-item"><span class="source-num">32</span><a href="https://www.bbguy.org/2023/02/01/099/" target="_blank">Blood Bank Guy - RhIG Teaching Episode</a></div>
          </div>
        </section>

        <footer style="margin-top: 3rem; padding-top: 2rem; border-top: 1px solid var(--color-border); text-align: center; color: var(--color-text-light); font-size: 0.85rem;">
          <p>Generated January 2026 | AI-Assisted Research</p>
          <p>This article is for educational purposes. Always consult institutional policies and current guidelines for clinical decisions.</p>
        </footer>
      </article>
    </main>
  </div>

  <button class="back-to-top" id="backToTop" aria-label="Back to top">‚Üë</button>

  <script>
    // Reading progress
    window.addEventListener('scroll', () => {
      const winScroll = document.documentElement.scrollTop;
      const height = document.documentElement.scrollHeight - document.documentElement.clientHeight;
      document.getElementById('progress').style.width = (winScroll / height * 100) + '%';
      document.getElementById('backToTop').classList.toggle('visible', winScroll > 500);
    });

    // Back to top
    document.getElementById('backToTop').addEventListener('click', () => {
      window.scrollTo({ top: 0, behavior: 'smooth' });
    });

    // Theme toggle
    function toggleTheme() {
      document.documentElement.toggleAttribute('data-theme');
      localStorage.setItem('theme', document.documentElement.hasAttribute('data-theme') ? 'dark' : 'light');
    }

    // Load saved theme
    if (localStorage.getItem('theme') === 'dark') {
      document.documentElement.setAttribute('data-theme', 'dark');
    }

    // Mobile sidebar toggle
    function toggleSidebar() {
      document.getElementById('sidebar').classList.toggle('open');
    }

    // Scroll spy for TOC
    const observer = new IntersectionObserver((entries) => {
      entries.forEach(entry => {
        const id = entry.target.getAttribute('id');
        const tocLink = document.querySelector(`.toc-link[href="#${id}"]`);
        if (tocLink) {
          if (entry.isIntersecting) {
            document.querySelectorAll('.toc-link').forEach(link => link.classList.remove('active'));
            tocLink.classList.add('active');
          }
        }
      });
    }, { rootMargin: '-20% 0px -80% 0px' });

    document.querySelectorAll('h2[id], h3[id]').forEach(heading => observer.observe(heading));

    // Smooth scroll for TOC links
    document.querySelectorAll('.toc-link').forEach(link => {
      link.addEventListener('click', (e) => {
        e.preventDefault();
        const target = document.querySelector(link.getAttribute('href'));
        if (target) {
          target.scrollIntoView({ behavior: 'smooth' });
          // Close mobile sidebar
          document.getElementById('sidebar').classList.remove('open');
        }
      });
    });

    // Detail panel functions for regulatory hierarchy
    function showDetail(type) {
      document.getElementById('overlay').classList.add('active');
      document.getElementById('panel-' + type).classList.add('active');
    }

    function closePanel() {
      document.getElementById('overlay').classList.remove('active');
      document.querySelectorAll('.detail-panel').forEach(panel => {
        panel.classList.remove('active');
      });
    }

    document.addEventListener('keydown', (e) => {
      if (e.key === 'Escape') closePanel();
    });

    // Initialize Chart.js for missed doses chart
    document.addEventListener('DOMContentLoaded', function() {
      const ctx = document.getElementById('missedDosesChart');
      if (ctx) {
        new Chart(ctx.getContext('2d'), {
          type: 'bar',
          data: {
            labels: ['Missing Orders', 'Communication Barriers', 'Documentation Gaps', 'Workflow Complexity'],
            datasets: [{
              label: 'Number of Missed Doses',
              data: [5, 4, 4, 4],
              backgroundColor: [
                'rgba(220, 38, 38, 0.8)',
                'rgba(249, 115, 22, 0.8)',
                'rgba(234, 179, 8, 0.8)',
                'rgba(59, 130, 246, 0.8)'
              ],
              borderColor: [
                'rgb(220, 38, 38)',
                'rgb(249, 115, 22)',
                'rgb(234, 179, 8)',
                'rgb(59, 130, 246)'
              ],
              borderWidth: 2,
              borderRadius: 8,
              borderSkipped: false
            }]
          },
          options: {
            responsive: true,
            maintainAspectRatio: true,
            indexAxis: 'y',
            plugins: {
              legend: { display: false },
              title: {
                display: true,
                text: 'Root Causes of 17 Missed RhIG Doses',
                font: { size: 16, weight: '600' },
                color: '#1e3a5f',
                padding: { bottom: 20 }
              },
              tooltip: {
                backgroundColor: 'white',
                titleColor: '#1e3a5f',
                bodyColor: '#64748b',
                borderColor: '#e2e8f0',
                borderWidth: 1,
                padding: 12,
                displayColors: true,
                callbacks: {
                  label: function(context) {
                    const total = 17;
                    const percentage = ((context.raw / total) * 100).toFixed(0);
                    return `${context.raw} cases (${percentage}% of total)`;
                  }
                }
              }
            },
            scales: {
              x: {
                beginAtZero: true,
                max: 6,
                ticks: { stepSize: 1, color: '#64748b' },
                grid: { color: '#f1f5f9' },
                title: { display: true, text: 'Number of Cases', color: '#64748b', font: { size: 12 } }
              },
              y: {
                ticks: { color: '#1e3a5f', font: { weight: '500' } },
                grid: { display: false }
              }
            }
          }
        });
      }
    });
  </script>
</body>
</html>
